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Abstract
Introduction The anaphase-promoting complex (APC) is a
multiprotein complex with E3 ubiquitin ligase activity, which is
required for the ubiquitination of securin and cyclin-B. Moreover,
the mitotic spindle checkpoint is activated if APC activation is
prevented. In addition, several APC-targeting molecules such as
securin, polo-like kinase, aurora kinase, and SnoN have been
reported to be oncogenes. Therefore, dysregulation of APC may
be associated with tumorigenesis. However, the clinical
significance and the involvement of APC in tumorigenesis have
not been investigated.
Methods The expression of APC7 was immunohistochemically
investigated in 108 invasive ductal carcinomas of the breast and
its relationship with clinicopathologic parameters was examined.
The expression of APC7 was defined as positive when the
summed scores of staining intensities (0 to 3+) and stained
proportions (0 to 3+) exceeded 3+.
Results Positive APC7 expression was less frequent than its
negative expression when histologic (P = 0.009) or nuclear
grade (P = 0.009), or mitotic number (P = 0.0016) was
elevated. The frequency of APC7 negative expression was
higher in high Ki-67 or aneuploid groups than in low Ki-67 or
diploid groups.
Conclusion These data show that loss of APC7 expression is
more common in breast carcinoma cases with poor prognostic
parameters or malignant characteristics. They therefore suggest
that dysregulation of APC activity, possibly through
downregulation of APC7, may be associated with tumorigenesis
in breast cancer.
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Introduction
The anaphase-promoting complex (APC) is an E3 ubiquitin
ligase that controls mitotic progression [1,2]. APC is a pol-
ymeric protein complex composed of at least 11 subunits,
which contains tetratricopeptide repeat proteins (APC3, 5,
6, 7, and 8), a cullin homolog (APC2), and a ring-H2 finger
domain (APC11). APC requires two WD40 repeat-contain-
ing coactivators, Cdc20 and Cdh1, to recruit and select
various substrates at different stages of the cell cycle, and
it was recently suggested that APC3 and APC7 interact
with these APC activators [3]. APC promotes metaphase/
anaphase transition by ubiquitizing and degrading securin,
an inhibitor of separase that participates in the degradation
of the chromatic cohesion complex. APC also ubiquitinates
cyclin-B and accelerates its degradation during the late
mitotic to the G1 phase, which results in mitotic exit. In addi-
tion, APC is known to target various cell cycle regulatory
molecules, including spindle-associated protein, DNA rep-
lication inhibitors, and mitotic kinases.
Several molecules targeted by APC have been reported to
promote transformation. Pituitary tumor-transforming gene
(PTTG), a vertebrate analog of securin, has been reported
to be an oncogene [4], and cancerous tissues from
patients with leukemia, lymphoma, or testicular, ovarian,
breast, or pituitary cancer were found to over-express
PTTG [5-7]. It was further reported that the constitutive
expression of polo-like kinase (PLK), a serine/threonine
kinase that is involved in spindle formation, centrosome
cycles, and chromosome segregation [8], may induceR238APC = the anaphase-promoting complex; ER = estrogen receptor; PLK = polo-like kinase; PTTG = pituitary tumor transforming gene.
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R239tumor formation [9]. Several reports have suggested a role
for PLK in the progression and/or malignancy of human
cancers, such as glioma, and endometrial carcinoma,
breast, ovarian, and esophageal carcinoma [10-13]. Aurora
kinase, another serine/threonine kinase that is involved in
chromosome segregation and centrosome maturation [14],
has also been reported to be amplified in bladder, gastric,
breast, and colorectal cancers [15-18] and to have the abil-
ity to transform NIH3T3 cells [19]. Recently, SnoN, a neg-
ative regulator of Smad that is involved in the transforming
growth factor-β signaling pathway, was shown to be a tar-
get molecule for the APC [20,21] and to have transforming
potential [22]. It was also found that SnoN is amplified in
stomach, thyroid, and lung carcinoma and lymphoma [23].
APC-regulating molecules have also been reported to be
involved in transformation. RASSF-1A and Mad2, which
inhibit APC activity, were reported to be tumor suppressors
[24,25].
Chromosome instability is believed to contribute to malig-
nant transformation because the majority of malignant
human cancers exhibit chromosomal gain or loss [26] and
because mitotic defects including chromosome aberra-
tions are frequently found in malignant cancers [27-29].
Because of the roles played by APC in mitotic cell cycle
progression, the timely activation of APC is thought to be
important for maintaining accurate chromosome separa-
tion. In addition, a report indicating that the mitotic spindle
checkpoint was reached by preventing APC activation [30]
suggests that the dysregulation of APC may give rise to
abnormal chromosome segregation, resulting in aneu-
ploidy. The recent finding that APC5 deficiency in Dro-
sophila is accompanied by a mitotic defect, which included
aneuploidy, suggests a role for APC in the maintenance of
chromosome stability [31]. It can therefore be hypothesized
that the abnormal regulation of APC may be involved in
malignant transformation through chromosome instability.
However, it is not known whether the abnormal regulation
of APC, possibly through genomic mutation or the modula-
tion of APC components, is related to tumorigenesis. Fur-
thermore, whether dysregulation of APC is related to
clinical parameters in various human cancers is yet to be
determined. Thus, we investigated immunohistochemically
the levels of APC7 in various cancer tissues and found
weak APC7 expression in high-grade ductal carcinomas of
breast. Therefore, we were encouraged to investigate the
expression of APC7 in 108 breast carcinomas and to
examine the relationship between the expression of APC7
and clinicopathologic parameters.
Methods
Production of polyclonal antibodies against APC7
Polyclonal antibodies against mouse APC7 were raised in
a NZW rabbit by immunization with recombinant APC7
protein. Briefly, recombinant mouse APC7 proteins were
produced in Escherichia coli using a pET32 expression
vector system (Novagen, Madison, WI, USA). The resulting
6× histidine-tagged APC7 proteins were purified by Ni-
NTA affinity chromatography (Qiagen, Hilden, Germany). A
NZW rabbit was then immunized with the purified APC7
protein and boosted twice. Blood was collected from the
auricular artery, and serum was prepared by clotting and
differential centrifugal separation (10,000 g for 10 min).
APC7-specific antibodies were further purified by binding
serum to APC7-coupled nitrocellulose and eluting with
100 mmol/l glycine–HCl buffer (pH 2.5).
Immunoblotting and immunoprecipitation
Protein extracts were prepared by solubilizing cells in RIPA
buffer (150 mmol/l NaCl, 1% NP40, 0.5% deoxycholate,
0.1% sodium dodecylsulfate, 50 mmol/l Tris.Cl, pH 7.5,
protease inhibitors) and differential centrifugation (10,000
g for 10 min). Of the protein fractions obtained, 30 µg was
resolved by 12% SDS-PAGE, and then the separated pro-
teins were electrotransferred onto Immobilon membranes
(Millipore, Bedford, MA, USA). After preblocking these
membranes with 5% skimmed milk, they were treated with
anti-mouse APC7 or human APC7 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) antibodies as primary antibody
and horseradish peroxidase-conjugated anti-rabbit anti-
bodies as secondary antibody. Immunoreactive bands were
developed using an electrogenerated chemiluminescence
system (Amersham Pharmacia Biotech, Uppsala, Sweden).
Immunoprecipitation was carried out with anti-human
APC3 antibodies (Transduction Laboratory, San Diego,
CA, USA) or anti-mouse APC7 antibodies. Subconfluent
cells were collected and then lysed by incubation on ice for
15 min in EBC buffer (0.5% Nonidet P-40, 40 mmol/l
Tris.HCl, pH 8.0, 120 mmol/l NaCl, 10 µg/ml aprotinin, 10
µg/ml leupeptin, 10 µg/ml PMSF). Cell lysates (1 mg) col-
lected by differential centrifugation (12,000 g for 15 min)
were mixed with 1 µg anti-human APC3 antibodies or anti-
APC7 antibodies, and these mixtures were then further
incubated for 1 hour at 4°C. Immune complexes were col-
lected by incubating with 30 µl of 50% protein A-sepha-
rose slurry for 1 hour and centrifugation (10,000 g for 15
s). After washing three times with ice-cold EBC buffer, the
pellets were suspended in 2× loading buffer (125 mmol/l
Tris.HCl, pH 6.8, 4% SDS, 20% glycerol, 14.4 mmol/l 2-
mercaptoethanol) and boiled for 5 min. Immunoblotting
was carried out with anti-human APC3, anti-human APC6
(Santa Cruz Biotechnology), or anti-mouse APC7
antibodies.
Tissue samples
Paraffin wax embedded blocks containing breast tumor tis-
sues resected from 108 patients diagnosed as having inva-
sive ductal carcinoma of breast at Wonju Christian Hospital
(Wonju, Korea) between January 1996 and May 2001
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years (mean 47.5 years). All procedures were performed in
accordance with our hospital's ethical guidelines, and
approval for the study was granted by the university hospi-
tal's ethics committee. All patients provided informed
consent.
Pathologic examination
Hematoxylin–eosin stained slides were reviewed, and his-
tologic grade was determined in terms of tubule formation,
nuclear pleomorphism and mitosis, using the criteria
described by Bloom and Richardson [32]. Tumor size, lym-
phatic metastasis, and clinical stage were determined
according to the American Joint Committee on Cancer cri-
teria [33].
Immunohistochemistry and evaluation
Specimens were fixed in 10% buffered formaldehyde and
embedded in paraffin using routine methods. Sections 5
µm thick were placed on silane-coated glass slides, dried
at 50°C for 2 hours, deparaffinized in xylene, rehydrated in
graded ethanol, and then washed in distilled water. To
retrieve antigenicity, the sections were dipped in citrate
buffer (10 mmol/l, pH 6.0) in a tender cooker (Nordic Ware,
Minneapolis, MN, USA) and then warmed for 15 min in a
microwave oven. Endogenous peroxidase activity was
blocked by pretreating with 0.3% hydrogen peroxide for 10
min. After washing with 50 mmol/l Tris buffer (pH 7.5), pri-
mary antibodies, namely anti-mouse APC7, human APC7,
human Ki-67 (DAKO, Copenhagen, Denmark), or estrogen
receptor (ER) antibodies (Novocastra, Newcastle, UK),
were applied overnight at a dilution of 1:50 or 1:100. The
sections were then further incubated for 20 min in a 1:50
dilution of biotinylated goat anti-rabbit or rabbit anti-mouse
antibody (DAKO) as secondary antibody. Color was devel-
oped by incubating with streptavidin peroxidase (DAKO)
for 20 min and staining with 3-amino-9-ethylcarazole.
Counter-staining was carried out with hematoxylin before
mounting. To obtain relevant staining equivalence of APC7
in different carcinoma tissues, an unstained tissue sample
and a strongly stained tissue sample were used as negative
and positive control, respectively. Whenever a staining pro-
cedure was performed, negative and positive control tis-
sues were simultaneously stained with new battery of
tissues and then the control tissues were used as a staining
reference.
All slides were examined by three pathologists and scores
were determined by consensus. The immunohistochemical
intensity of APC7 was awarded an 'intensity' score of 0 to
3+, with 0 represented an unstained nucleus and 3+ the
strongest staining intensity. The 'proportion' score repre-
sented the estimated percentage of stained cells as a frac-
tion of all tumor cells in the microscopic field (i.e. 0 = 0%,
1+ = 0–25%, 2+ = 25–50%, and 3+ = >50%). Because
true negative expression with a staining intensity of 0 was
very rare (six cases/108 tissue samples), and therefore the
statistical significance between APC7 expression and clin-
icopathologic parameters could not obtained, we included
a weak APC7 expression group (34 cases/108 tissue sam-
ples) with staining intensity of 1 and proportion score of 1
in the negative group. Therefore, a summed intensity and
proportion score of ≥ 3+ was defined as positive APC7
expression whereas a score of ≤ 2+ was defined as nega-
tive. The Ki-67 labeling index was defined as the percent-
age of positively stained cells in five to seven high power
fields (×400). At least 1000 cells per field were counted.
Nuclear ER staining was also examined at ×400 and com-
pared with a strong positive control. ER staining intensity
was designated weak, moderate, or strong. Positive reac-
tivity was defined when the proportion of cells exhibiting
moderate to strong staining exceeded 10%.
DNA analysis
Two 50-µm sections were cut from each paraffin block,
deparaffinized in xylene, rehydrated in a descending etha-
nol series, and then washed in phosphate-buffered saline.
The sections were then placed in 10 mmol/l citrate solution
(pH 6.0) and incubated for 2 hours at 80°C. After cooling,
1 mg/ml pepsin in 0.1 N HCl was added and the sections
were digested for 30 min. The resulting suspension (2 ×
106 nuclei) was filtered through 50 µ-mesh and further sus-
pended in 500 µl of 1% bovine serum albumin solution.
DNAs were stained using a Cycle TEST PLUS DNA Rea-
gent Kit™ (Becton Dickinson, Ontario, Canada). Stained
cells were analyzed using a FACscan (Becton Dickinson,
San Jose, CA, USA) and the fraction of aneuploid cells was
calculated using Cell Fit software (Becton Dickinson).
Statistical analysis
Statistical analysis was performed using the SPSS ver.
10.0 program (SPSS Inc., Chicago, IL, USA). The associa-
tion between APC7 expression and clinicopathologic
parameters was analyzed using χ2 tests. P ≤ 0.05 was con-
sidered statistically significant.
Results
Characterization of polyclonal antibodies against APC7
In this study we isolated a novel gene (GenBank Accession
Number: AF076607) and identified it as the mouse APC7
gene (GenBank Accession Number: BC006635). It was
found to have 97.7% homology with its human counterpart
(GenBank Accession Number: AF191340). Polyclonal
antibodies were raised by immunizing a NZW rabbit with
recombinant mouse APC7 proteins (amino acids 88–565),
and the APC7-specific antibodies so obtained were then
purified by affinity binding to APC7-coupled nitrocellulose.
Immunoblotting analysis of MCF-7 human breast carci-
noma extracts showed that these purified antibodies and
human APC7 antibodies (sc-20987; Santa Cruz)
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reactivity was APC7-specific (Fig. 1A, panels a and b). The
antibodies recognized same sized antigens from mouse
and human cells (Fig. 1A, panel c). Moreover, APC7 anti-
bodies precipitated both APC3 and APC6 components in
mouse and human derived cells, whereas human CDC27
(APC3) antibodies precipitated APC6 and APC7 compo-
nents (Fig. 1B), thus demonstrating that the antigen recog-
nized by our purified antibody is the APC7 component of
the APC. Immunohistochemical studies on the paraffin-
embedded sections of normal breast tissues showed that
the purified APC7 antibodies recognized antigens located
in the nucleus (Fig. 1C, panel a), which is in accordance
with the finding that most APC antigens are localized in
nucleus during the interphase [33]. Immune reactivity, as
shown by immunohistochemistry, was also APC7 specific
(Fig. 1C, panel b).
Expression of APC7 in various human tissues
To search for differentially expressed APC7 in normal and
cancerous tissues, we performed immunohistochemical
analyses with the purified mouse APC7 antibodies using
Figure 1
Recognition of anaphase-promoting complex (APC)7 antigen with anti-mouse APC7 antibodies. (A) Panel a shows immunoblotting of human MCF-
7 breast carcinoma cell extracts with affinity-purified anti-mouse APC7 polyclonal antibodies before (-) and after (+) prebinding APC7 antibodies to 
recombinant mouse APC7-coupled nitrocellulose. Panel b shows immunoblotting with human APC7 polyclonal antibodies (Santa Cruz; sc-20987). 
Panel c shows immunoblotting of human Hela cervical carcinoma, mouse NIH 3T3 fibroblast, and human breast carcinomas (MCF, MCF-7; MDA, 
MDA-MB-231; SK, SK-BR-3; HS, HS 578T) with purified mouse APC7 antibodies. Cell extracts were resolved on 12% SDS-PAGE and the sepa-
rated proteins were electrotransferred onto Immobilon membranes (Millipore). The membranes were then treated with anti-APC7 antibodies and 
horseradish peroxidase-conjugated anti-rabbit IgG antibodies as primary and secondary antibodies, respectively. Immune reactive bands were devel-
oped using an electrogenerated chemiluminescence (ECL) system. (B) Immunoprecipitation and immunoblotting of mouse 3T3 and human Hela cell 
extracts with anti-human APC3 (CDC27; Transduction Laboratory) or purified anti-mouse APC7 antibodies. After mixing cytosolic extracts (1 mg) 
with pre-immune rabbit sera (2 µl), anti-APC3 (1 µg), or anti-mouse APC7 antibodies (1 µg), precipitates were fractionated on 12% SDS-PAGE. 
After electrotransfer, immunoblotting was performed with anti-APC3, anti-human APC6 (Santa Cruz Biotech), or anti-mouse APC7 antibodies as pri-
mary antibodies. Peroxidase-conjugated anti-mouse, anti-goat, or anti-rabbit IgG antibodies were bound as secondary antibodies and developed 
using the ECL system. (C) Immunohistochemistry of normal breast tissues with purified anti-mouse APC7 antibodies before (panel a) and after 
(panel b) prebinding APC7 antibodies to recombinant mouse APC7-coupled nitrocellulose (original magnification ×200). After binding the purified 
anti-mouse APC7 antibodies and the biotinylated goat anti-rabbit antibodies as primary and secondary antibodies, respectively, a streptavidin-perox-
idase kit (DAKO) was used to detect APC7 antigen. Staining and counter-staining were then performed using 3-amino-9-ethylcarazole and hematox-
ylin, respectively.
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cores. We compared the APC7 expressions of the cores
by assessing the averaged staining intensities (0 to 3+).
Staining of ≥ 2+ was defined as positive expression and of
≤ 1+ as negative expression. Table 1 lists the APC7
expression of 17 normal and 22 tumor tissues with multiple
cores. Positive staining was observed in rapid growing nor-
mal epithelial tissues. In contrast, slow growing but more
differentiated tissues such as skeletal muscle, adipocytes,
spinal cord, brain, and basal stromal tissues near epithelial
cells exhibited no or weak immune reactivity to APC7. In
addition, slowly growing tumors such as chondrosarcomas,
lipomas, low-grade urothelial carcinomas, and renal cell
carcinomas tended to show weak reactivity to APC7,
whereas most tumor tissues with high proliferation rate
were positive. Interestingly, some ductal carcinomas of the
breast with an undifferentiated high histologic grade exhib-
ited weak reactivity to APC7.
Relationship between APC7 expression and 
clinicopathologic parameters in breast carcinomas
To determine whether the loss of APC7 expression is
related to tumorigenesis in breast cancer, we scrutinized
the expression level of APC7 immunohistochemically in
108 invasive ductal carcinomas of the breast and then
searched for correlations with clinocopathologic parame-
ters. Figure 2A shows the representative features of APC7
staining scores of 0 to 3+, and Fig. 2B shows the immuno-
blotting results for three representative tissues with differ-
ent intensity scores. These data show that APC7 staining
intensity was proportional to band intensity by immunoblot-
ting, demonstrating that immunohistochemical staining
intensities represent APC7 expression. Typical negative
and positive APC7 expressions in breast carcinoma are
shown in Fig. 2C panels a and b. The ratios of APC7-posi-
tive to APC-negative expression and their relationships with
various clinicopathologic parameters are summarized in
Table 2. Of breast carcinomas, 63% exhibited positive
APC7 expression and 37% were negative. APC7 expres-
sion did not correlate with tumor size (P = 0.8180) or
metastasis (P = 0.9703). No statistical significance was
found between clinical stage (0.2798) and APC7 expres-
sion, or between ER expression (0.1031) and APC7
expression. Nevertheless, the frequency of positive APC7
expression tended to be lower in clinical stage III (58.3%)
than in stage I (78.9%) tumors, and in patients who were
ER negative (52.9%) than in those who were ER positive
(70.6%). In contrast, negative APC7 expression was high-
est in stage III tumors and in those who were ER negative.
On the other hand, the negative expression of APC7 was
positively correlated with higher histologic grade (P =
0.001), nuclear grade (P = 0.0090), mitotic number (P =
0.0016), Ki-67 index (P = 0.0078), and aneuploidy (P =
0.0095). Moreover, APC7 expression was more frequent in
those with a low histologic grade (84.8%) than in those
with a high grade (35.0%). Because histologic grade is
determined by nuclear pleomorphism, mitotic number, and
tubule formation, those with a high nuclear grade and a
high mitotic number also exhibited a similar negative corre-
lation with APC7 expression. The frequency of positive
APC7 expression was lower in the high Ki-67 group than in
the low Ki-67 group. About 82% (77/94) of tissue samples
were classified as aneuploid. Nearly half of the aneuploid
group exhibited a low level of APC7 expression (42.9%),
whereas most of the diploid group showed positive APC7
expression (94.1%), indicating that breast carcinomas with
normal ploidy express higher levels of APC7.
Table 1
Expression of APC7 in various human tissues
Expression of APC7a Tissue type
Normal tissue Tumor tissue
Negative Adipocytes, brain, hepatocytes, skeletal muscle cells, 
spinal cord
Lipoma, pleomorphic adenoma of salivary gland, low grade 
urothelial carcinoma, chondrosarcoma, adenoid cystic 
carcinoma, renal cell carcinoma, high grade ductal 
carcinoma of breast
Positive Basal cells of epidermis, bronchial epithelium, ductal cells 
of breast, ductal cells of pancreas, ductal cells of salivary 
glands, endometrial glands, kidney epithelium, gastric 
mucosa, prostate glands and ducts, urothelial epithelium, 
fibroblasts, germinal center cells
Adenocarcinoma of colon, adenocarcinoma of 
endometrium, adenocarcinoma of pancreas, 
adenocarcinoma of prostate, adenocarcinoma of 
stomach, ductal carcinoma of pancreas, hepatocellular 
carcinoma, high grade urothelial carcinoma, papillary 
serous carcinoma of ovary, squamous cell carcinoma of 
esophagus, squamous carcinoma of cervix, 
leiomyosarcoma of uterus, malignant lymphoma, 
melanoma, seminoma of testis
aImmunohistochemical data from tissue arrays (Tissue-Array Co., Seoul, Korea) stained with anti-anaphase-promoting complex (APC)7 antibodies. 
Tissue-array slides mounted with 50 normal or 50 tumor cores contained 17 normal or 22 tumor tissues, respectively, in triplicate or duplicate. 
Negative APC7 expression is represented by staining intensities of 0 or 1+, whereas positive expression is represented by staining intensities of 
2+ or 3+, as designated in Fig. 2A. Average staining intensities of several cores were used to determine tissue expression.
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carcinomas
To determine whether the expression of the APC7 compo-
nent is exclusively modulated in breast carcinoma, we
investigated the expression levels of other APC compo-
nents. We first performed immunohistochemic analysis
using anti-human APC3 antibodies or anti-human APC6
antibodies. However, we could not obtain meaningful data
because nuclei in all breast carcinoma tissues were
strongly stained by these antibodies, probably because of
nonspecific cross-reactivity. Next, we compared the
expression levels of APC3 and APC6 components by
immunoblotting. However, immunoblotting analysis with
anti-human APC6 antibodies also failed to exhibit a distinct
band in tumor tissues because of the weak immune reactiv-
ity and the nonspecific reactivity of the APC6 antibody.
Thus, we were able to obtain expression data on APC3 in
various breast carcinoma tissues, in conjunction with APC7
expression.
Figure 3 shows immunoblotting results for APC3 and
APC7 in 24 representative breast carcinoma tissues. The
expression levels of APC3 and APC7 in these tissues was
variable, which might have been due to variable APC
expression in these tissues. Some tissues (lanes 1, 2, 3, 8,
9, 13, 14, and 15) exhibited relatively high levels of expres-
sion of both APC3 and APC7, whereas other tissues (lanes
6, 7, 16, and 22) showed no expression of APC3 and
APC7. These data suggest that the expression levels of
APC3 and APC7 are simultaneously regulated in some
Figure 2
Representative immunohistochemical and immunoblotting analysis of anaphase-promoting complex (APC)7 in invasive ductal carcinomas of the breast
breast. (A) Invasive ductal carcinomas stained by APC7 antibody with intensity scores of 0 to 3+ (original magnification, ×400). After binding with 
anti-mouse APC7 antibodies as primary antibodies and with biotinylated anti-rabbit antibodies as secondary antibodies, streptavidin peroxidase was 
bound to the biotinylated antibodies. Staining was conducted with 3-amino-9-ethylcarazole and hematoxylin. (B) Immunoblotting of three breast tis-
sues with APC7 intensities ranging from 0 to 3+. Immunoblotting was carried out using affinity-purified APC7 antibodies and peroxidase-conjugated 
anti-rabbit IgG antibodies as primary and secondary antibodies, respectively. Electrogenerated chemiluminescence was used to detect positive 
bands. (C) Representative negative (panel a) and positive (panel b) APC7 immunostaining of invasive ductal breast carcinoma with histologic grades 
of 3 and 2, and staining intensities of 0 and 3+, respectively. Immunohistochemical staining was also performed using a streptavidin peroxidase kit.
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Relationship between APC7 expression and various clinicopathological parameters in invasive ductal carcinomas of the breast
Characteristics All cases APC7 positive APC7 negative Pa (significance)
All carcinomas 108 (100%) 68 (63.0%) 40 (37.0%)
Tumor size 0.8180 (NSb)
Small (<5 cm) 81 (100%) 51 (63.0%) 30 (37.0%)
Large (≥ 5 cm) 27 (100%) 17 (63.0%) 10 (37.0%)
Metastasis 0.9703 (NS)
Negative 47 (100%) 29 (61.7%) 18 (38.3%)
Positive 61 (100%) 39 (63.9%) 22 (36.1%)
Clinical stage 0.2798 (NS)
I 19 (100%) 15 (78.9%) 4 (21.1%)
II 65 (100%) 39 (60.0%) 26 (40.0%)
III 24 (100%) 14 (58.3%) 10 (41.7%)
ERc 0.1031 (NS)
Positive 51 (100%) 36 (70.6%) 15 (29.4%)
Negative 51 (100%) 27 (52.9%) 24 (47.1%)
Histologic grade 0.001
I 33 (100%) 28 (84.8%) 5 (15.2%)
II 55 (100%) 33 (60.0%) 22 (40.0%)
III 20 (100%) 7 (35.0%) 13 (65.0%)
Nuclear grade 0.0090
1 6 (100%) 6 (100%) 0 (0%)
2 87 (100%) 57 (65.5%) 30 (34.5%)
3 15 (100%) 5 (33.3%) 10 (66.7%)
Mitotic number (n/10 hpfd) 0.0016
<10 49 (100%) 37 (75.5%) 12 (24.5%)
10–19 41 (100%) 26 (63.4%) 15 (36.6%)
≥20 18 (100%) 5 (27.8%) 13 (72.2%)
Ki-67 labeling indexe 0.0078
L (<25.5) 63 (100%) 58 (76.2%) 15 (23.8%)
H (≥ 25.5) 41 (100%) 20 (48.8%) 21 (51.2%)
DNA ploidyf 0.0095
Diploidy 17 (100%) 16 (94.1%) 1 (5.9%)
Aneuploidy 77 (100%) 44 (57.1%) 33 (42.9%)
aχ2 test. bNot significant (P > 0.05). cEstrogen receptor (ER): because of an insufficient amount of some carcinoma tissues, we could not obtain 
meaningful ER staining data from six of the 108 breast carcinoma tissues. dhpf, high power field. eKi-67 (%): labeling index of Ki-67. The H and L 
groups were categorized in terms of being higher or lower than the mean index (25.5) in all cases. The mean indices of the L and H groups were 
22.17 and 31.79, respectively. Because of an insufficient amount of some carcinoma tissues, we could not obtain meaningful Ki-67 staining data 
from four of the 108 breast carcinoma tissues. fDNA ploidy: in some cases we did not perform flow cytometry because of insufficient tissues. In 
another case, we could not interpret DNA ploidy data because of a high coefficient of variance (over 8.0). We obtained meaningful data for 94 
tissue samples.
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nomas (lanes 4, 11, 12, 23, and 24) showed relatively high
APC3 expression but low APC7, suggesting that selective
downregulation of APC7 is unique to some breast
carcinomas.
Discussion
This work was undertaken to determine whether the
expressional modulation of APC7 is related to tumorigene-
sis in human cancers. We first used immunohistochemistry
to investigate the expression of APC7 in tissue array slides
mounted with various cancer tissues, and we observed
strong immune reactivity to APC7 in the most rapidly
growing tumor tissues. However, some breast cancer tis-
sues with a high histologic grade exhibited weak immune
reactivity to APC7. Therefore, we scrutinized APC7 expres-
sion in 108 invasive ductal carcinomas of the breast and
compared these findings with clinicopathologic parame-
ters. Although positive immune reactivity to APC7 was
observed in more than 60% of breast carcinomas, negative
APC7 expression was frequently observed in breast carci-
nomas with more aggressive characteristics (i.e. a higher
histologic grade, a higher nuclear grade, a higher prolifera-
tion rate, or aneuploidy). These findings suggest a possible
association between the expression of APC7 and breast
cancer tumorigenesis.
Most components of APC have been reported to be
expressed in growing tissues at fairly constant levels [34].
On the other hand, Gieffers and coworkers [35] reported
that components of APC (i.e. APC2, APC3, and APC7) are
expressed in postmitotic adult brain tissue. However, it is
not known how the expressions of APC components are
modulated according to growth or cell differentiation. We
observed twofold APC7 modulation in mouse NIH3T3 cells
according to cell cycle (data not shown). In the present
study, immunohistochemical studies using normal and can-
cer tissue arrays showed that APC7 is highly expressed in
most proliferating cells. Strong immunoreactivity to APC7
was restricted to normal epithelial tissues and proliferating
cancer tissues, whereas low APC7 immunoreactivity was
observed in slow growing and differentiated tissues, such
as adipocytes, hepatocytes, muscle cells, brain, and spinal
cord, and in slowly growing tumor tissues such as lipoma,
pleomorphic adenoma of the salivary gland, adenoid cystic
carcinoma, chondrosarcoma, low-grade urothelial carci-
noma, and renal cell carcinoma.
Interestingly, we found a negative correlation between
APC7 expression and some high-grade breast carcinoma
tissues, and especially in those with aneuploidy. This nega-
tive correlation seems to be unique to some malignant
breast carcinomas because we did not observe significant
loss of APC7 expression in other aggressive carcinomas. In
fact, we further investigated APC7 expression in two repre-
sentative carcinomas, namely lung and renal carcinomas
(i.e. rapid and slow growing carcinomas, respectively; data
not shown), and obtained the same result as that obtained
using the tissue array. All rapidly growing carcinoma tis-
sues examined showed positive APC7 expression,
whereas over 90% of slow growing renal carcinomas
showed negative APC7 expression. Reports that the level
of APC1 expression in breast cancer tissue is lower than
that in other cancer tissues, and that expressed sequence
tags of APC7 are reduced in breast tissues [36] support
our observation that the loss of APC7 expression seems to
be restricted in some high-grade breast carcinomas. Immu-
noblotting analysis showed that the expression of APC7
was variable in different breast carcinomas, which appears
to be due to differences in expression of APC7 between
individual breast carcinomas. However, the possibility of
epithelial cell contamination during tissue extraction cannot
be excluded. In several breast carcinomas, the loss of
APC7 expression was accompanied by the loss of another
APC component, such as APC3, but other tissues exhib-
ited selective APC7 downregulation. These observations
demonstrate that a unique loss of APC7 expression occurs
in some breast carcinomas, and suggest that regulation of
APC components in breast carcinomas is heterogeneous.
Our data agree with reports that the expressional patterns
of APC components are not simultaneously modulated [37]
and that APC components can be individually modulated
by environmental stimuli [38].
It has been reported that chromosome instability through
abnormal mitotic progression plays a critical role in tumor
malignancy [38,39]. Therefore, the dysregulation of APC
Figure 3
Immunoblotting analysis of breast carcinoma using anti-anaphase-pro-oting complex (APC)3 and APC7 antibodies
moting complex (APC)3 and APC7 antibodies. Protein extracts were 
prepared from 24 ductal breast carcinoma tissues by homogenizing tis-
sues in EBC buffer for 1 min and centrifuging (12,000 g for 15 min). Of 
protein from each tissue, 30 µg was fractionated by 12% SDS-PAGE 
and transferred to Immobilon membranes. Immunoblotting analysis was 
also carried out using anti-APC3 or APC7 antibodies as primary anti-
bodies, and horseradish peroxidase-conjugated anti-mouse or anti-rab-
bit IgG antibodies as secondary antibodies, and bands were then 
detected by electrogenerated chemiluminescence.
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R246activation, which probably perturbs mitotic progression,
may affect malignant transformation or tumor progression.
Moreover, the finding that APC is required for the G2 and
mitotic checkpoints suggests that malignant transformation
can be caused by chromosome instability through the dys-
regulation of APC activation [40]. Recently, Wang and
coworkers [41] reported a genetic alteration in APC6 and
APC8 in human colon cancer cells, and suggested their
involvement in colon carcinogensis. Aneuploidy is fre-
quently observed in breast cancer tissues [42], and APC
target molecules such as PTTG, PLK, and aurora kinase are
often upregulated in the same tissues [7,12,17],
supporting the notion that dysregulation of APC may play a
role in the tumorigenesis of breast cancer.
Our data concerning the negative correlation between
APC7 expression and a high histologic grade with aneu-
ploidy supports a possible linkage between the
downregulation of APC7 and malignant transformation in
breast cancer. As several papers have reported lethality
induced by the loss of APC components [43,44], our
observation raises the question as to how the cell cycle can
progress in the absence of APC7. Although defects in the
spindle checkpoint could elicit cell death, cancer cells in
conjunction with p53 mutation could override the mitotic
checkpoint and the cell lethality elicited by abnormal mito-
sis [41]. In this situation, it is believed that an abnormality in
APC regulation could induce unscheduled mitotic progres-
sion [31]. One interesting observation was that the cell
cycle of mutant APC8-harboring cells progressed, even
with a disturbed pattern [45]. A recent report that the
expression of cyclin-B1 in breast cancer cells was sus-
tained in the G1 phase suggests that the cell cycle can
progress in the presence of an abnormal mitotic cell cycle
machinery [46]. Therefore, we hypothesize that cells with a
functional APC defect can drive cell cycle progression in a
situation in which cyclin-B has accumulated. However, the
mechanism that allows breast cancer cells to progress
through mitosis with functionally defective APC remains
unknown.
We did not determine whether APC7 expression is corre-
lated with disease-free survival because most of the
patients had recently been diagnosed. However, our data
demonstrate that the downregulation of APC7 is more
common in those who exhibit markers of poor prognosis. A
number of parameters, namely lymph node metastases,
tumor size, histologic grade, ER and progesterone receptor
expression, lymphovascular invasion, proliferation rate,
DNA content, and expression of oncogenes, have been
reported to influence the prognosis of women with breast
cancer [47]. On the other hand, in the present study poor
prognostic indications such as high histologic grade, high
proliferation rate, and aneuploidy were found to be related
to downregulation of APC7, which suggests that breast
cancer patients exhibiting weak APC7 expression would
have poor survival. Yoshimoto and coworkers [48] reported
that histologic grade and clinical stage, including lymph
node metastasis, are important prognostic markers in
breast cancer patients, which supports the notion that the
downregulation of APC7 can be a viable prognostic
marker. An earlier report that the Ki-67 index is related to
histologic grade also supports the prognostic significance
of the negative correlation between APC7 and proliferation
[49].
Conclusion
We found that downregulation of APC7 in breast carci-
noma is more common in those with high histologic grade
and high proliferation rate, and in those showing aneu-
ploidy. Therefore, downregulation of APC7 may be a
marker of a poor prognosis and may contribute to breast
cancer tumorigenesis via chromosome instability and/or
accelerated oncogenic signaling.
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